Secukinumab: A New Treatment Option for Psoriatic Arthritis.

ABSTRACT:

Introduction

Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy associated with impaired physical function and reduced quality of life. Biologic therapies that target tumor necrosis factor (anti-TNF) have significantly improved clinical outcomes. Partial, non- and transient responses remain common comprising significant unmet clinical need. New therapies with novel modes of action are urgently required.

Objectives

The interleukin (IL)-17 pathway has recently been attributed a critical role in the pathogenesis of spondyloarthritides. Herein, we review data from clinical studies with secukinumab, a novel fully human IgG1κ anti-IL-17A monoclonal antibody (mAb), in patients with active PsA.

Results

Across two pivotal phase 3 studies, secukinu

SUBMITTER: Mease P 

PROVIDER: S-EPMC4999581 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature